Pharmaceutical

Sandoz concludes acquisition of Mycamine antifungal agent from Astellas

Novartis division Sandoz has concluded the acquisition of global brand rights for the antifungal agent Mycamine from Astellas.

Aug 28, 2023 - 20:00
Sandoz concludes acquisition of Mycamine antifungal agent from Astellas
Novartis division Sandoz has concluded the acquisition of global brand rights for the antifungal agent Mycamine from Astellas.
Read the original article

Tags:

Previous Article

Phebra, University of Wollongong partner to develop cancer therapies

Next Article

Janssen submits sBLA to FDA for NSCLC combination therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial

STAT+: Pfizer to halt development of its twice-daily or...

Dec 1, 2023

Pharma’s contractors might finally be on the rebound

Pharma’s contractors might finally be on the rebound

Feb 15, 2024

STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro

STAT+: New obesity drugs are in the works trying to out...

Sep 12, 2023